Mizuho analyst Mara Goldstein downgraded TCR2 Therapeutics (TCRR) to Neutral from Buy with a price target of $1.72, down from $20. The firm expects the company’s merger with Adaptimmune (ADAP) to close in Q2.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on TCRR:
- TCR² Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update
- TCR2 Therapeutics reports Q4 EPS ($1.56), consensus (79c)
- TCR2 Therapeutics downgraded to Hold from Buy at Jefferies
- TCR2 Therapeutics downgraded to Hold from Buy at Truist
- TCR2 Therapeutics downgraded to Neutral from Buy at H.C. Wainwright